Lancet:瑞芬太尼自控镇痛用于产前阵痛

2018-08-14 zhangfan MedSci原创

研究认为瑞芬太尼病人自控镇痛对于分娩阵痛的控制效果优于哌替啶,有望成为分娩镇痛的新一线方法

据统计在需接受分娩镇痛的人群中,约1/3采用哌替啶硬膜外注射,在缓解疼痛的同时增加了阴道分娩助产机械的使用风险。瑞芬太尼病人自控镇痛(PCA)是一种哌替啶替代方法,目前尚未得到广泛使用。近日研究人员对二者镇痛效果的差异进行了比较。

研究在14个英国妇产中心开展,16岁以上,孕37周以上,单胎头位且需要阿片类镇痛的产妇参与研究,随机接受静脉瑞芬太尼PCA(40μg 每次,最小间隔给药时间2min)或肌内哌替啶(每4小时100mg,24小时给药不超过400mg)。研究的主要终点为分娩镇痛后仍需接受硬膜外镇痛的比例。

201名产妇接受PCA,199人接受哌替啶。瑞芬太尼PCA组中19%的产妇接受硬膜外镇痛(39/201),而哌替啶组为41%(81/199),比值比为0.48。研究期间未发生镇痛药物导致的不良反应。

研究认为瑞芬太尼病人自控镇痛对于分娩阵痛的控制效果优于哌替啶,有望成为分娩镇痛的新一线方法。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-10-18 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-08-16 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-08-16 xue8602
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-08-16 qilu_qi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1829753, encodeId=53071829e5341, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 18 14:03:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355286, encodeId=e8d7135528668, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384825, encodeId=5ff9138482578, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405264, encodeId=798914052648d, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502532, encodeId=4d6b15025321b, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Aug 16 00:03:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338520, encodeId=d5c83385200a, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Tue Aug 14 10:22:44 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-08-14 lietome24

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

相关资讯

Anesth Analg:艾司洛尔对胃食管交接区的影响:14名健康志愿者随机、双盲的交叉研究

被动的反流可能发生在整个围手术期,增加肺部误吸和术后肺部并发症的风险。食管胃交界区(EGJ)是阻止胃内容物被动反流的屏障。在麻醉期间使用的催眠药和阿片样物质,特别是瑞芬太尼已证明能降低食管胃交界处(EGJ)中的压力。通常用于抵抗心动过速和高血压的艾司洛尔已被证明在全身麻醉期间具有很强的实用性。像瑞芬太尼一样,β1-肾上腺素受体拮抗剂可用于减轻气管插管的应激反应,并改变围手术期麻醉需求。也可能减少术

Anesthesia & Analgesia:右美托咪定与瑞芬太尼用于支气管内超声引导下支气管针吸活检术的监护性麻醉:随机对照试验

本研究假设,与瑞芬太尼相比,在非插管患者中右美托咪定用于支气管内超声引导下支气管针吸活检术(EBUS-TBNA)的监护性麻醉(MAC),较少引起主要呼吸系统不良事件发生(呼吸过缓、呼吸暂停和氧饱和度下降的发作次数),但围手术期满意度无差异。

瑞芬太尼引起的痛觉过敏

在麻醉诱导及维持过程中,镇痛是不可或缺而且是极其重要的一部分。瑞芬太尼是一种新型超短效阿片类镇痛药物,具有起效快、半衰期短、消除迅速、连续输注无蓄积、术后无苏醒延迟或者呼吸抑制,以及代谢不依赖于肝肾功能的特点,而其消除又不受年龄、性别、体重的影响,因此作为麻醉维持用药在各类手术的麻醉中得到广泛应用。但是研究表明,瑞芬太尼可以以剂量依赖的方式引起痛觉过敏及药物耐受,导致患者术后对其他阿片类药物需

瑞芬太尼诱发痛觉过敏相关受体机制的研究进展

作者:贾娟,兰州大学第二临床医学院;石翊飒,兰州大学第二医院麻醉科 阿片类药物引起的痛觉过敏(opioid-induced hyperalgesia,OIH)是指使用阿片类药物后痛觉阈值降低,对正常的疼痛刺激更加敏感。瑞芬太尼作为超短效阿片类镇痛药,代谢不受肝、肾功能影响,主要由血浆非特异性酯酶水解,具有起效迅速、半衰期短的特性。相比于其他阿片类镇痛药物,瑞芬太尼更容易发生

瑞芬太尼较硝酸甘油更增强脑组织缺氧耐受性

  南昌大学第一附属医院张学康、曾而明等发表的一项研究表明,瑞芬太尼控制性降压用于急性高容量血液稀释(AHH)后的颅内动脉瘤夹闭术病人,可降低脑氧代谢率,增强脑组织对缺氧的耐受性,比硝酸甘油控制性降压更具优越性。该论文发表在《中国微侵袭神经外科杂志》[2012,17(3):100-103]。   该研究收集了30例颅内动脉瘤夹闭术病人,并随机等分为硝酸甘油组和瑞芬太尼组。手术开始时以15~20&